All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML

July 15th 2024

The investigational menin-MLL inhibitor DSP-5336 has received FDA fast track designation in KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.

FDA Completes End-of-Phase 2 Meeting for Annamycin Plus Cytarabine in AML

July 15th 2024

Moleculin Biotech completed an end-of-phase 2 meeting with the FDA regarding the investigation of annamycin plus cytarabine in acute myeloid leukemia.

The Shifting MCL Treatment Paradigm Raises Sequencing Questions

July 15th 2024

Tycel Phillips, MD, expands on the treatment paradigm for patients with mantle cell lymphoma, highlighting recent data read-outs and FDA approvals/withdrawals

Differentiation Therapy in Acute Myeloid Leukemia: Not Just for APL Anymore

July 15th 2024

Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.

City of Hope CAR T-Cell Therapy for Advanced Prostate Cancer Demonstrates Positive Results in Phase 1 Clinical Trial

July 15th 2024

Preliminary data from a first-in-human phase 1 trial using a CAR T-cell therapy developed by City of Hope researchers has been published in Nature Medicine.

Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy

July 14th 2024

Natural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.

FDA Awards Fast Track Designation to CT-0525 for HER2-Overexpressing Solid Tumors

July 14th 2024

The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.

Temple University Hospital and Fox Chase Cancer Center Researchers Characterize HER2 Mutations in Patients With Lung Adenocarcinoma

July 13th 2024

Innovative Research Continues to Propel Individualized GIST Treatments

July 13th 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing GIST research for GIST Awareness Day.

Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across Subgroups

July 12th 2024

Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.

Abemaciclib Monotherapy Does Not Elicit Responses in Advanced Renal Cell Carcinoma

July 12th 2024

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC

July 12th 2024

Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.

Belzutifan Shows Manageable, Pooled Safety Profile in Advanced VHL-Associated RCC

July 12th 2024

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Ongoing Research Aims to Identify Treatment Approaches for Non–Clear Cell RCC Subtypes

July 12th 2024

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

No OS Difference Observed After Various Immunotherapy/TKI Regimens in Advanced RCC

July 12th 2024

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC

July 12th 2024

Health Canada has approved osimertinib/chemotherapy for advanced non–small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.

Epcoritamab Shines in Third-Line Follicular Lymphoma With the Potential to Move into Earlier Lines

July 12th 2024

Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs.

Ochsner Health Wins Innovator Award Funds for Connected MOM

July 12th 2024

The HHS competition evaluated the effectiveness of Ochsner Connected MOM in increasing blood pressure monitoring during pregnancy and the postpartum period.

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

July 12th 2024

As the lung cancer paradigm continues to advance, increasingly effective therapies are under development for previously underserved disease subtypes.

Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC

July 11th 2024

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.